Express Scripts to buy rival NextRx from WellPoint
Tuesday, April 14, 2009 - 02:21
in Mathematics & Economics
Prescription benefit manager Express Scripts Inc. said Monday that it would buy rival NextRx from WellPoint Inc. for $4.68 billion in cash and stock.